North America ACE Inhibitors Market to Grow with a CAGR of 5.25% through 2029
Growing
prevalence of cardiovascular diseases is expected to drive the North America
ACE Inhibitors Market in the forecast period 2025-2029
According to TechSci
Research report, “ACE Inhibitors Market – North America Industry Size, Share,
Trends, Competition Forecast & Opportunities, 2029”, the North
America ACE Inhibitors Market stood at USD 2.18 Billion in 2023 and is
anticipated to grow with a CAGR of 5.25% in the forecast period. ACE inhibitors are pivotal in cardiovascular
drug therapy, targeting cardiovascular conditions by relaxing blood vessels and
lowering blood pressure. This market is crucial in the pharmaceutical sector,
notably in North America, where cardiovascular diseases are escalating. The
increasing incidence of ailments like hypertension, coronary artery disease,
and heart failure has fueled the need for efficient treatments, establishing
ACE inhibitors as vital in managing cardiovascular health issues.
Browse
over XX market data Figures spread through XX Pages and an in-depth TOC on "North America ACE Inhibitors
Market”
The North America ACE Inhibitors Market is a vital
segment of the pharmaceutical industry, addressing cardiovascular conditions
like hypertension and heart failure. With a growing burden of cardiovascular
diseases in the region, ACE inhibitors play a crucial role in managing and
treating these conditions. Factors such as the aging population, lifestyle
changes, and the prevalence of comorbidities contribute to the market's growth.
Technological advancements, research and development activities, and strategic
collaborations further drive market expansion. As demand for effective
cardiovascular therapies rises, the North America ACE Inhibitors Market
continues to evolve to meet the healthcare needs of the population.
The North America ACE
Inhibitors Market is segmented into type, drug, dosage form, application, end
user, region, and company.
Based on drugs, Ramipril
stands out as dominant in the North America market. Its popularity stems from
several factors, including its proven efficacy in managing hypertension and
heart failure, favorable safety profile, and widespread use in clinical
practice. Ramipril offers once-daily dosing convenience, enhancing patient
compliance. Clinical studies have demonstrated its effectiveness in reducing
the risk of cardiovascular events, making it a preferred choice for many
healthcare providers. Its long-standing presence in the market, coupled with
extensive research and positive patient outcomes, solidifies Ramipril's
position as a leading ACE inhibitor in North America.
Based on application, Hypertension
emerges as the dominant condition among Heart Failure, Chronic Kidney Disease,
Hypertension, Diabetes, Heart Attack, and others in the ACE Inhibitors market.
The prevalence of hypertension is notably high, affecting a significant portion
of the population. ACE inhibitors are widely recognized as first-line therapy
for hypertension due to their efficacy in reducing blood pressure and
preventing cardiovascular complications. Hypertension often coexists with other
cardiovascular conditions, further driving the demand for ACE inhibitors. Given
their established efficacy and widespread use, ACE inhibitors, including
Ramipril and Enalapril, remain the preferred choice for managing hypertension,
solidifying their dominance in the market.
Based on end user, Hospitals
emerge as the dominant distribution channel among Hospitals, Online Drug
Stores, and others in the ACE Inhibitors market. Hospitals serve as primary
points of care for patients with cardiovascular conditions, facilitating direct
access to ACE inhibitors upon prescription by healthcare professionals. Hospitals
typically stock a wide range of pharmaceuticals, including ACE inhibitors,
ensuring availability for patients requiring immediate treatment. While online
drug stores offer convenience and accessibility, hospitals maintain prominence
due to their established infrastructure, expertise in cardiovascular care, and
ability to provide comprehensive treatment solutions, consolidating their
position as the dominant distribution channel for ACE inhibitors.
Major
companies operating in North America ACE Inhibitors Market are:
- Pfizer Inc
- Novartis AG
- Johnson & Johnson
- Merck KGaA
- Sanofi S.A
- Bayer AG
- United Therapeutics
Corporation
- Teva Pharmaceutical
Industries Ltd.
- Bristol-Myers Squibb
- Takeda
Pharmaceuticals Company Ltd.
Download Free Sample Report
Customers
can also request 10% free customization on this report.
“The ACE Inhibitors Market
holds a promising future, driven by advancements in healthcare, escalating
cardiovascular disease burdens, and evolving treatment strategies. Ongoing
research and development efforts aim to introduce more targeted and innovative
ACE inhibitors, offering patients improved therapeutic options with fewer side
effects. Personalized medicine will gain prominence, ensuring tailored
treatments for individual patients. The adoption of telemedicine and digital
healthcare will improve accessibility and treatment adherence. With the aging
population and increasing awareness of hypertension, the demand for ACE
inhibitors is projected to remain robust. Pharmaceutical companies have ample
opportunities to innovate and address the evolving needs of patients in the
market's future” said Mr. Karan Chechi, Research Director with TechSci
Research, a research-based management consulting firm.
“North America ACE Inhibitors
Market By Type (Sulfhydryl-containing Agents, Dicarboxylate-containing
Agents, Phosphonate-containing Agents), By Drug (Ramipril, Enalapril,
Benazepril, Fosinopril, Captopril, Moexipril, Others), By Dosage Form (Oral
Tablets, Oral Solutions), By Application (Heart Failure, Chronic Kidney
Disease, Hypertension, Diabetes, Heart Attack, Others), By End user (Hospitals,
Online Drug Stores, Others), By
Region, By Competition Forecast &
Opportunities, 2029F”,
has evaluated the future growth potential of North America ACE Inhibitors
Market and provides statistics & information on market size, structure and
future market growth. The report intends to provide cutting-edge market
intelligence and help decision makers take sound investment decisions. Besides,
the report also identifies and analyzes the emerging trends along with
essential drivers, challenges, and opportunities in North America ACE
Inhibitors Market.
Contact
Techsci Research LLC
420 Lexington Avenue,
Suite 300,
New York, United
States- 10170
Tel: +13322586602
Email: [email protected]
Website: www.techsciresearch.com